FibroGenFGEN
About: FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
Employees: 225
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2,975% more call options, than puts
Call options by funds: $369K | Put options by funds: $12K
31.63% less ownership
Funds ownership: 32.67% [Q1] → 1.05% (-31.63%) [Q2]
45% less capital invested
Capital invested by funds: $10.2M [Q1] → $5.62M (-$4.6M) [Q2]
50% less funds holding
Funds holding: 56 [Q1] → 28 (-28) [Q2]
90% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 29
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 25
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Matthew Keller | 310%upside $43 | Buy Maintained | 7 Aug 2025 |
Financial journalist opinion
Based on 5 articles about FGEN published over the past 30 days
